Clinical Edge Journal Scan

Atopic dermatitis risk in children associated with residential distance from highly trafficked segments


 

Key clinical point: Children living closer to highly trafficked segments (HTS) are at a greater risk of developing atopic dermatitis (AD).

Major finding: Children living at ≥1,000 vs <500 m from an HTS had 27% lower odds of developing AD (P = .0009). The odds of AD decreased by 21% (P = .0002) with each factor of 10 increase in the distance from an HTS.

Study details: The data come from a retrospective cross-sectional analysis of 7247 children aged 0-18 years with AD and 7247 age- and sex-matched control individuals without AD.

Disclosures: This study was supported by the Department of Pediatrics, Division of Allergy and Clinical Immunology, National Jewish Health, Denver, Colorado, and Eugene F and Easton M Crawford Charitable Lead Unitrust, Chicago, Illinois. D Leung reported ties with various organizations.

Source: Nevid MZ et al. The association of residential distance from highly trafficked roads with atopic dermatitis risk. J Allergy Clin Immunol Pract. 2023 (Mar 20). Doi: 10.1016/j.jaip.2023.03.021

Recommended Reading

Topical delgocitinib shows promise for chronic hand eczema, pivotal trial shows
MDedge Dermatology
JAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trial
MDedge Dermatology
Commentary: IL-31 inhibitor, e-cigarettes, and upadacitinib in AD, April 2023
MDedge Dermatology
What are the clinical implications of recent skin dysbiosis discoveries?
MDedge Dermatology
Phase 3 trials support lebrikizumab for moderate-to-severe atopic dermatitis
MDedge Dermatology
Baricitinib shows promise in pediatric patients with moderate-to-severe atopic dermatitis
MDedge Dermatology
Baricitinib allows flexibility in dosing regimens up to 104 weeks in moderate-to-severe atopic dermatitis
MDedge Dermatology
Topical tacrolimus and corticosteroids show similar efficacy and impact on airways in childhood atopic dermatitis
MDedge Dermatology
Maternal atopic dermatitis linked with the risk for childhood- and adult-onset atopic dermatitis
MDedge Dermatology
Abrocitinib offers comparable efficacy between adults and adolescents with moderate-to-severe atopic dermatitis
MDedge Dermatology